Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allerdent is a fully functional, commercial-grade toothpaste platform designed to deliver personalized allergy immunotherapy through daily tooth brushing. This approach, known as oral mucosal immunotherapy (OMIT), allows for the incorporation and stabilization of allergenic proteins (specific to each patient’s allergies) into the toothpaste base. When used as directed, these proteins are delivered to the oral mucosa—areas rich in immune cells responsible for initiating desensitization—thereby helping patients build tolerance to environmental allergens such as pollens, dust mites, animal dander, and molds. The product can be customized by physicians with up to 10 different allergen extracts per patient and is intended primarily for respiratory allergies like allergic rhinitis. Developed by Dr. William Reisacher at Weill Cornell Medicine and commercialized by Allovate Therapeutics, Allerdent offers an alternative to traditional subcutaneous or sublingual immunotherapy methods[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Allerdent.